CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 12 enrolled
Drug / intervention
RDEA3170 10 mg +1 moredrug
Likely dose
RDEA3170 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02279641
NCT02279641Phase 1Completed
CompareCT.gov

A Phase 1b, Randomized, Open-label Study to Evaluate the Potential Pharmacokinetic and Pharmacodynamic Interactions Between RDEA3170 and Allopurinol in Adult Male Subjects With Gout

Ardea Biosciences, Inc.·interventional·Posted Oct 31, 2014·Updated Dec 20, 2017

In Brief

A Phase 1 clinical trial evaluating RDEA3170 10 mg and allopurinol 300 mg for Gout. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This is a Phase 1b, randomized, open-label, drug-drug interaction study in adult male subjects with gout. It is designed to assess the pharmacokinetics (PK) and pharmacodynamics (PD) of RDEA3170 or allopurinol alone and in combination in the fed state.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGout
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 31, 2014
Enrollment StartNov 1, 2014
Primary CompletionApr 6, 2015
Study CompletionSep 11, 2015
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 11.7 years ago

Interventions

RDEA3170 10 mgdrug

allopurinol 300 mgdrug